Upgrade

Kazia Therapeutics Limited

KZIA

Last
$8.93
Day
+1.2%
1y
+22.8%
5y
-98.5%
52w
-49.3%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
—
EMA 21
10.01
EMA 50
11.16
EMA 200
11.04
20d high
-24.2%
5y high
-98.6%
5y range
1th
Website · 6 employees · Australia

Positions held

Your positions

KZIA isn't in your positions.

Add it to see shares, cost, and P&L here.

Score
1
Hold
watch
Signal
Neutral
Target
$10.04
Stop
$7.80
Stop distance
12.7%
Target vs last
+12.4%

Fundamentals

Market cap$100.79MEnterprise value$30.62MTrailing P/E—Forward P/E-740.97
PEG1.01Price / book3.10Beta2.27Dividend yield0.00%
Revenue growth3.1%Earnings growth—Gross margin100.0%Operating margin-146.4%
Profit margin0.0%ROE-106.9%ROA-25.7%Debt / equity0.00
Current ratio2.87Free cash flow$1.10MAnalyst recommendationnoneMean target$28.35
52w high$17.4052w low$4.86

Quarterly

No data yet.

Yearly (6y)

2025202420232022
Revenue$0.0M$2.3M$0.0M$0.0M
Op margin-33850.0%-1233.2%——
Net income-$20.7M-$26.8M-$20.5M-$25.0M
Gross margin————
Gross profit————
Operating income-$14.2M-$28.5M-$24.1M-$25.4M
Headline scan

No flags

• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).

News

2026-09-22 · Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

2026-09-22 · Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

2026-09-22 · Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

2026-09-19 · Bank of New York Mellon Corporation (BNY) Lost A Depositary Mandate

2026-09-09 · Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

2026-09-09 · Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

2026-09-09 · Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

2026-09-09 · Kazia (KZIA) Raises Approximately $40M in Gross Proceeds and Expands Paxalisib. Is the Capital Base Stronger than the Clinical Evidence?

2026-09-01 · Kazia Therapeutics Reports Preclinical Tumor Reduction in Colorectal Cancer Study

2026-09-01 · Kazia Therapeutics Expands Paxalisib Trial Into HR+/HER2- Breast Cancer

2026-09-01 · Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

2026-09-01 · Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

KZIA · daily-19.2% over 13 sessions
Close EMA21 EMA50 EMA200
8.589.289.9810.6811.382026-092026-092026-092026-092026-102026-102026-10